Chronic Heart Failure

1. Overview

Heart failure (HF) is a complex clinical syndrome resulting from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. [1] It represents a major and growing public health problem, affecting over 64 million people worldwide. [2]

Key Definitions

• Heart Failure: Clinical syndrome characterized by symptoms (dyspnea, fatigue, ankle swelling) and signs (elevated JVP, pulmonary crackles, peripheral edema) resulting from structural or functional cardiac abnormality, leading to reduced cardiac output and/or elevated intracardiac pressures at rest or during stress. [1]

• Chronic Heart Failure: Heart failure symptoms present for > 3 months with evidence of persistent cardiac dysfunction. Distinguished from acute heart failure by gradual onset and compensatory mechanisms.

Epidemiology

Heart failure is the only major cardiovascular disease with increasing incidence and prevalence. [3]

• Prevalence: 1-2% of adult population in developed countries; rises to > 10% among people aged > 70 years. [1]
• Incidence: Approximately 5-10 per 1000 population per year. [3]
• Lifetime Risk: 20-25% at age 40 years. [4]
• Hospital Admissions: Leading cause of hospitalization in patients > 65 years. [5]
• Mortality: 5-year mortality approximately 50%, comparable to many malignancies. [6]
• Economic Burden: Accounts for 1-2% of total healthcare expenditure in developed countries. [7]

Classification Systems

1. Classification by Left Ventricular Ejection Fraction (LVEF)

The primary classification system used in clinical practice and research: [1]

Clinical Note: HFmrEF was introduced in 2016 ESC guidelines to identify patients who may have recovered from HFrEF or are in transition to HFrEF. [8] Treatment evidence is strongest for HFrEF, with emerging evidence for HFpEF.

2. New York Heart Association (NYHA) Functional Classification

Based on symptom severity and exercise limitation: [9]

• Class I: No limitation. Ordinary physical activity does not cause symptoms.
• Class II: Slight limitation. Comfortable at rest, but ordinary activity causes fatigue, palpitation, or dyspnea.
• Class III: Marked limitation. Less than ordinary activity causes symptoms. Comfortable only at rest.
• Class IV: Symptoms at rest. Unable to carry out any physical activity without discomfort.

3. ACC/AHA Staging System

Emphasizes disease progression and prevention: [10]

• Stage A: At risk (hypertension, diabetes, coronary disease) but no structural disease or symptoms.
• Stage B: Structural disease (e.g., previous MI, LV hypertrophy) but no symptoms.
• Stage C: Structural disease with prior or current symptoms.
• Stage D: Refractory heart failure requiring specialized interventions.

---

2. Pathophysiology

Heart failure is not a single disease but a syndrome resulting from diverse cardiac insults leading to common pathophysiological pathways. [11]

Initial Cardiac Insult

Common causes of myocardial damage:

1. Ischemic Heart Disease (60-70% of cases): Myocardial infarction leads to loss of contractile myocardium and regional wall motion abnormalities. [12]

2. Chronic Hypertension (10-15%): Sustained afterload elevation causes concentric LV hypertrophy, initially compensatory but eventually leading to diastolic dysfunction and decompensation. [13]

3. Cardiomyopathy:

   • Dilated Cardiomyopathy (DCM): Idiopathic (30-40%), viral myocarditis (10-15%), genetic/familial (20-30%), alcohol-induced (5-10%). [14]
   • Hypertrophic Cardiomyopathy (HCM): Genetic sarcomeric protein mutations causing asymmetric septal hypertrophy and diastolic dysfunction.
   • Restrictive Cardiomyopathy: Infiltrative diseases (amyloidosis, sarcoidosis) causing impaired ventricular filling.

4. Valvular Heart Disease (10%): Chronic volume overload (mitral/aortic regurgitation) or pressure overload (aortic stenosis). [1]

5. Other Causes:

   • Arrhythmia-induced (chronic atrial fibrillation)
   • Toxic (chemotherapy - anthracyclines, trastuzumab)
   • Nutritional deficiency (thiamine deficiency, selenium deficiency)
   • Endocrine (thyrotoxicosis, hypothyroidism)
   • Peripartum cardiomyopathy
   • Infiltrative (hemochromatosis, glycogen storage disease)

Ventricular Remodeling

Following initial insult, the heart undergoes progressive structural and functional changes: [15]

Molecular Changes:

• Myocyte hypertrophy with altered gene expression
• Myocyte apoptosis and necrosis
• Alterations in calcium handling proteins (SERCA2a downregulation)
• Changes in contractile protein expression (β-myosin heavy chain upregulation)

Cellular Changes:

• Myocyte loss and slippage
• Interstitial fibrosis (collagen deposition)
• Inflammatory cell infiltration
• Altered extracellular matrix

Chamber Changes:

• HFrEF Pattern: Ventricular dilation, increased end-diastolic and end-systolic volumes, eccentric hypertrophy, spherical LV geometry, increased wall stress, reduced contractility.
• HFpEF Pattern: Concentric hypertrophy, reduced chamber size, increased wall thickness, impaired relaxation, elevated filling pressures despite normal/near-normal EF.

Neurohormonal Activation

The hallmark of heart failure progression is activation of compensatory mechanisms that ultimately become maladaptive: [16]

1. Renin-Angiotensin-Aldosterone System (RAAS)

Activation Sequence:

1. Reduced renal perfusion → Renin release from juxtaglomerular apparatus
2. Renin cleaves angiotensinogen → Angiotensin I
3. ACE converts Angiotensin I → Angiotensin II
4. Angiotensin II stimulates aldosterone release from adrenal cortex

Effects of RAAS Activation:

• Angiotensin II: Systemic vasoconstriction (↑ afterload), renal sodium/water retention (↑ preload), myocyte hypertrophy, collagen synthesis, pro-inflammatory effects, endothelial dysfunction.
• Aldosterone: Sodium/water retention, potassium excretion, myocardial and vascular fibrosis, baroreceptor dysfunction, sympathetic activation.

Therapeutic Target: ACE inhibitors, ARBs, ARNIs, mineralocorticoid receptor antagonists (MRAs).

2. Sympathetic Nervous System (SNS)

Activation Triggers: Baroreceptor dysfunction, reduced cardiac output, peripheral chemoreceptor stimulation.

Effects:

• Increased heart rate (↑ myocardial oxygen demand)
• Increased contractility (initially compensatory)
• Peripheral vasoconstriction (↑ afterload)
• Renin release (activating RAAS)
• Direct myocyte toxicity (β1-receptor-mediated apoptosis)
• Arrhythmogenesis

Therapeutic Target: Beta-blockers (β1-selective: bisoprolol, metoprolol; non-selective: carvedilol).

3. Natriuretic Peptide System

Counter-regulatory System: Represents the body's attempt to counteract RAAS and SNS activation.

Peptides:

• ANP (Atrial Natriuretic Peptide): Released from atrial myocytes in response to stretch.
• BNP (B-type Natriuretic Peptide): Released from ventricular myocytes in response to increased wall stress.
• CNP (C-type Natriuretic Peptide): Endothelial origin, local paracrine effects.

Effects: Natriuresis, vasodilation, inhibition of RAAS and SNS, anti-fibrotic effects, lusitropy (improved relaxation).

Degradation: Neprilysin enzyme breaks down natriuretic peptides, reducing their beneficial effects.

Therapeutic Target: Neprilysin inhibitors (sacubitril in ARNI combination).

4. Arginine Vasopressin (AVP)

Effects: Water retention (V2 receptors in kidney), vasoconstriction (V1a receptors), hyponatremia.

Therapeutic Target: Vaptans (tolvaptan) - limited role in routine practice.

Hemodynamic Consequences

Frank-Starling Mechanism: Initially compensatory increase in preload improves stroke volume, but eventually plateaus and chamber dilation becomes detrimental.

Laplace's Law: Wall stress = (Pressure × Radius) / (2 × Wall Thickness)

• Ventricular dilation increases wall stress
• Increased wall stress → ↑ myocardial oxygen demand
• Hypertrophy attempts to normalize wall stress but contributes to diastolic dysfunction

Cardiac Output: CO = Stroke Volume × Heart Rate

• Reduced stroke volume due to impaired contractility (HFrEF) or filling (HFpEF)
• Compensatory tachycardia initially maintains CO but ↑ oxygen demand and ↓ diastolic filling time

Elevated Filling Pressures: Lead to pulmonary and systemic venous congestion, explaining congestive symptoms.

Peripheral Adaptations

Skeletal Muscle Changes:

• Fiber type shift (Type I → Type II)
• Mitochondrial dysfunction
• Reduced oxidative enzyme activity
• Muscle atrophy
• Explains exercise intolerance independent of cardiac output

Endothelial Dysfunction: Impaired nitric oxide production, enhanced endothelin-1 release, contributing to peripheral vasoconstriction and exercise limitation.

Renal Changes: Reduced GFR, increased tubular sodium reabsorption, activation of tubuloglomerular feedback, worsening fluid retention (cardiorenal syndrome).

---

3. Clinical Features

Symptoms

Heart failure symptoms result from elevated filling pressures (congestive symptoms) and/or reduced cardiac output (low output symptoms). [1]

Congestive Symptoms (Fluid Overload)

Dyspnea (90% of patients):

• Exertional Dyspnea: Earliest symptom. Quantify by NYHA class or specific activities (e.g., stairs climbed, distance walked).
• Orthopnea: Dyspnea when lying flat. Caused by redistribution of fluid from lower extremities to thorax, increasing pulmonary capillary pressure. Ask: "How many pillows do you sleep on?"
• Paroxysmal Nocturnal Dyspnea (PND): Sudden dyspnea awakening patient from sleep 2-4 hours after lying down. More specific for HF than orthopnea.
• Bendopnea: Dyspnea when bending forward (e.g., tying shoes). Emerging symptom with high specificity for HF. [17]

Other Congestive Symptoms:

• Ankle/leg swelling (dependent edema)
• Abdominal bloating/distension (ascites)
• Right upper quadrant pain (hepatic congestion)
• Early satiety, nausea (bowel edema, hepatic congestion)
• Weight gain (> 2 kg in 3 days suggests fluid retention)

Low Output Symptoms

• Fatigue: Most common symptom but least specific. Results from reduced skeletal muscle perfusion and intrinsic muscle abnormalities.
• Exercise Intolerance: Inability to perform previously tolerated activities.
• Dizziness/Lightheadedness: Particularly on standing (orthostatic hypotension).
• Cognitive Impairment: "Brain fog," difficulty concentrating (reduced cerebral perfusion).
• Nocturia: Fluid mobilization when supine; also increased ANP/BNP release.

Other Symptoms

• Palpitations: Due to atrial fibrillation (present in 30-50% of HF patients), ventricular arrhythmias, or compensatory sinus tachycardia.
• Cough: Typically dry, worse when lying down (pulmonary congestion).
• Wheezing: "Cardiac asthma" due to airway edema/bronchial hyperreactivity.
• Syncope: Concerning symptom suggesting arrhythmia or severe low output.

Signs

General Inspection

• Cachexia: Cardiac cachexia (involuntary weight loss > 5% in 6 months) in advanced HF; poor prognosis.
• Respiratory Distress: Use of accessory muscles, tachypnea (> 20 breaths/min).
• Cyanosis: Central cyanosis in severe cases.

Vital Signs

• Pulse: Tachycardia (HR > 100 at rest), irregularly irregular (AF), low volume (reduced stroke volume), alternating pulse amplitude (pulsus alternans - sign of severe LV dysfunction).
• Blood Pressure: May be elevated (hypertensive HF), normal, or low (advanced HF, poor prognosis if SBP less than 90 mmHg).
• Respiratory Rate: Tachypnea (> 20/min).
• Oxygen Saturation: May be reduced, especially with pulmonary edema.

Cardiovascular Examination

Jugular Venous Pressure (JVP):

• Elevated JVP (> 4 cm above sternal angle at 45°): Most specific sign for elevated right atrial pressure. [18]
• Hepatojugular Reflux: Sustained rise in JVP (> 3 cm) with right upper quadrant pressure for 15 seconds; indicates elevated right-sided filling pressures.
• JVP Waveform: Prominent V wave (tricuspid regurgitation), absent Y descent (constrictive physiology).

Precordial Examination:

• Displaced Apex Beat: Laterally displaced (> 5th intercostal space, >midclavicular line) and inferiorly displaced; indicates LV dilatation. Thrusting, sustained character in volume overload.
• Parasternal Heave: Right ventricular hypertrophy/dilatation.
• Palpable S3: Low-frequency vibration at apex in early diastole (advanced HF).

Auscultation:

• Heart Sounds:
  • "S1: May be soft (reduced contractility)."
  • "S2: Widely split if LBBB present; loud P2 if pulmonary hypertension."
  • "S3 Gallop: Pathological third heart sound in adults; heard in early diastole at apex; highly specific for HF (85-90% specificity). [19] Represents rapid ventricular filling into stiff, dilated ventricle."
  • "S4: Atrial gallop; heard in late diastole; indicates reduced ventricular compliance (diastolic dysfunction)."
  • "Summation Gallop: S3 + S4 merge with tachycardia."
• Murmurs:
  • "Mitral Regurgitation: Functional MR common in HFrEF due to annular dilatation and papillary muscle displacement; pansystolic murmur at apex radiating to axilla."
  • "Tricuspid Regurgitation: Pansystolic murmur at left lower sternal border, increases with inspiration (Carvallo's sign)."
  • "Aortic Stenosis: Ejection systolic murmur radiating to carotids (cause of HF)."

Respiratory Examination

• Inspection: Tachypnea, use of accessory muscles, pursed-lip breathing.
• Percussion: Dullness at lung bases (pleural effusion).
• Auscultation:
  • "Bibasal Crackles: Fine inspiratory crackles; represent alveolar fluid. Present in 60-70% of acute decompensated HF but may be absent in chronic compensated HF due to lymphatic compensation."
  • "Pleural Effusion: Reduced breath sounds, stony dull percussion. Typically bilateral or right-sided; isolated left effusion should prompt search for alternative cause."
  • Wheeze: Bronchial edema causing airway narrowing ("cardiac asthma").

Abdominal Examination

• Hepatomegaly: Smooth, tender liver edge in right upper quadrant; indicates hepatic congestion.
• Ascites: Shifting dullness, fluid thrill; indicates severe right heart failure or constriction.
• Pulsatile Liver: Tricuspid regurgitation.

Peripheral Examination

• Edema: Pitting edema of ankles/feet (mobile patients) or sacrum (bedridden). Press for 5 seconds; grading:
  • "Grade 1+: 2 mm depression, disappears rapidly"
  • "Grade 2+: 4 mm depression, disappears in 10-15 seconds"
  • "Grade 3+: 6 mm depression, lasts > 1 minute"
  • "Grade 4+: 8 mm depression, lasts 2-5 minutes"
• Peripheral Perfusion: Cool extremities (low output state), delayed capillary refill (> 2 seconds).
• Peripheral Pulses: Reduced volume, weak.

---

4. Diagnosis

Diagnostic Pathway

The diagnosis of heart failure is based on symptoms, signs, and objective evidence of cardiac dysfunction. [1]

Step 1: Clinical Assessment

Initial Presentation: Patient with symptoms suggestive of HF (dyspnea, fatigue, ankle swelling).

History and Examination: Assess symptoms (congestive vs. low output) and signs (elevated JVP, S3, displaced apex, edema).

Step 2: Natriuretic Peptide Testing

Rationale: High negative predictive value (> 95%); allows exclusion of HF in primary care without need for immediate echocardiography. [20]

Peptides:

• BNP (B-type Natriuretic Peptide): Half-life ~20 minutes
• NT-proBNP (N-terminal pro-BNP): Half-life ~120 minutes; more stable, preferred in most laboratories

Thresholds (for UNTREATED patients presenting with dyspnea): [1]

Causes of Elevated BNP/NT-proBNP (False Positives):

• Age > 70 years (levels increase with age)
• Atrial fibrillation (30-40% higher)
• Renal impairment (reduced clearance)
• Pulmonary embolism, COPD, pulmonary hypertension
• Sepsis, critical illness
• Liver cirrhosis (reduced clearance)

Causes of Low BNP/NT-proBNP (False Negatives):

• Obesity (adipose tissue expresses natriuretic peptide clearance receptors; reduce threshold by 50% if BMI > 35)
• Flash pulmonary edema (insufficient time for release)
• Very early presentation
• HFpEF with normal filling pressures at time of testing

Step 3: Electrocardiogram (ECG)

Utility: Normal ECG has high negative predictive value (~95%) for excluding HF, particularly HFrEF. [21] If ECG and natriuretic peptides both normal, HF is highly unlikely.

Typical ECG Findings:

• Sinus Tachycardia: Compensatory response
• Atrial Fibrillation: Present in 30-50% of HF patients; may be cause or consequence
• Q Waves: Previous myocardial infarction (ischemic etiology)
• Left Ventricular Hypertrophy (LVH): Sokolow-Lyon criteria, Cornell criteria
• Bundle Branch Block:
  • "LBBB (QRS > 120 ms): Present in 20-30% of HFrEF; indicates dyssynchrony and potential CRT candidacy"
  • "RBBB: Less specific"
• Poor R Wave Progression: V1-V4 (anterior MI or dilated cardiomyopathy)
• ST-T Changes: Ischemia, LV strain pattern
• Low Voltage: Amyloidosis, pericardial effusion, obesity

Step 4: Echocardiography (Definitive Diagnostic Test)

Modality: Transthoracic echocardiography (TTE) is the gold standard for assessing cardiac structure and function. [1]

Key Measurements:

1. Left Ventricular Ejection Fraction (LVEF):

   • Normal: 55-70%
   • HFrEF: less than 40%
   • HFmrEF: 41-49%
   • HFpEF: ≥50%
   • Methods: Biplane Simpson's method (most accurate), visual estimation, 3D echo

2. LV Dimensions and Volumes:

   • LV end-diastolic diameter (LVEDD): Normal less than 56 mm (men), less than 52 mm (women)
   • LV end-systolic diameter (LVESD): Normal less than 41 mm (men), less than 38 mm (women)
   • Increased volumes indicate dilatation

3. Wall Thickness:

   • Interventricular septum and posterior wall thickness
   • Normal: 6-11 mm
   • Hypertrophy: > 11 mm (concentric LVH, HCM, infiltrative disease)

4. Regional Wall Motion:

   • Assess 17-segment model
   • Hypokinesis, akinesis, dyskinesis indicate ischemic etiology

5. Valvular Function:

   • Exclude significant valvular disease as primary cause
   • Assess for functional mitral/tricuspid regurgitation secondary to dilatation

6. Diastolic Function (crucial for HFpEF diagnosis):

   • E/A Ratio: E-wave (early filling) / A-wave (atrial filling) velocity
     • Normal: 0.8-2.0
     • Impaired relaxation (Grade I): E/A less than 0.8
     • Pseudonormal (Grade II): E/A 0.8-2.0 with elevated E/e'
     • Restrictive (Grade III-IV): E/A > 2.0
   • E/e' Ratio: Early mitral inflow velocity / early diastolic mitral annular velocity
     • Normal: less than 8
     • Indeterminate: 8-14
     • Elevated filling pressures: > 14
   • Left Atrial Volume Index (LAVI):
     • Normal: less than 34 mL/m²
     • Mildly abnormal: 34-41 mL/m²
     • Severely abnormal: > 41 mL/m²
   • Tricuspid Regurgitation Velocity: Estimates pulmonary artery systolic pressure

7. Right Ventricular (RV) Function:

   • TAPSE (Tricuspid Annular Plane Systolic Excursion): Normal > 17 mm
   • RV Fractional Area Change: Normal > 35%
   • RV S' (Tissue Doppler): Normal > 9.5 cm/s

HFpEF Diagnostic Criteria (H2FPEF Score, HFA-PEFF Algorithm): [22]

• Symptoms/signs of HF
• LVEF ≥50%
• Elevated natriuretic peptides
• Evidence of structural (LA enlargement, LVH) or functional (diastolic dysfunction on echo) abnormalities

Step 5: Additional Investigations

Chest X-ray:

• Cardiomegaly: Cardiothoracic ratio > 50%
• Pulmonary Venous Congestion: Upper lobe blood diversion, cephalization
• Interstitial Edema: Kerley B lines (horizontal lines at bases)
• Alveolar Edema: Perihilar "bat wing" infiltrates
• Pleural Effusions: Blunting of costophrenic angles
• Not sensitive for chronic compensated HF but useful in acute presentations

Blood Tests:

1. Full Blood Count:

   • Anemia: Exacerbates HF symptoms; target Hb > 10 g/dL
   • Polycythemia: Chronic hypoxemia (cyanotic heart disease, COPD)

2. Urea and Electrolytes:

   • Hyponatremia: Marker of disease severity; RAAS/AVP activation; if Na less than 135 mmol/L, poor prognosis
   • Hyperkalemia: Risk with RAAS inhibitors + MRAs; monitor closely
   • Renal Function: Baseline and monitor with RAAS inhibitors; cardiorenal syndrome

3. Liver Function Tests:

   • Hepatic congestion: Elevated transaminases (ALT, AST), bilirubin
   • Chronic congestion: Elevated alkaline phosphatase

4. Thyroid Function: Exclude thyrotoxicosis or hypothyroidism as secondary cause

5. Glucose/HbA1c: Diabetes common comorbidity; SGLT2i beneficial regardless

6. Lipid Profile: Assess cardiovascular risk; statin if ischemic etiology

7. Iron Studies:

   • Ferritin and Transferrin Saturation: Iron deficiency common (40-50% of HF patients)
   • Iron deficiency defined as: Ferritin less than 100 μg/L OR ferritin 100-299 μg/L with transferrin saturation less than 20%
   • Treat with IV iron (ferric carboxymaltose) - improves symptoms and quality of life [23]

Cardiac Biomarkers:

• Troponin: Elevated in acute decompensation, myocardial strain, ischemia
• High-sensitivity Troponin: Chronically elevated in HF; marker of ongoing myocyte injury

Step 6: Identifying Etiology

Coronary Angiography:

• Indicated if: Known coronary disease, angina, evidence of ischemia, new-onset HF of uncertain cause
• Identifies ischemic vs. non-ischemic etiology
• Revascularization may improve LVEF if viable myocardium present

Cardiac MRI:

• Gold standard for LVEF measurement
• Tissue characterization: Late gadolinium enhancement (scar), T1/T2 mapping (edema, fibrosis, infiltration)
• Diagnose: Myocarditis, infiltrative cardiomyopathy (amyloidosis, sarcoidosis), HCM, ARVC

Genetic Testing:

• Indicated for dilated cardiomyopathy (30-40% genetic), HCM (60% sarcomeric mutations), ARVC
• Cascade screening of first-degree relatives if pathogenic variant identified

Endomyocardial Biopsy:

• Rarely required
• Indications: Suspected myocarditis, infiltrative disease, unexplained rapidly progressive HF

---

5. Management

Principles of Heart Failure Management

1. Identify and Treat Reversible Causes: Ischemia (revascularization), valvular disease (surgical correction), arrhythmia (rate/rhythm control), thyroid disease, alcohol cessation.

2. Guideline-Directed Medical Therapy (GDMT): Four-pillar therapy for HFrEF proven to reduce mortality and hospitalization. [1,24]

3. Device Therapy: ICD and CRT for selected patients with persistent LV dysfunction despite optimal medical therapy.

4. Symptom Management: Diuretics for congestion, optimize volume status.

5. Lifestyle Modifications: Diet (sodium restriction), exercise, fluid restriction (if appropriate), vaccinations, psychosocial support.

6. Comorbidity Management: Treat atrial fibrillation, hypertension, diabetes, anemia, iron deficiency, sleep apnea.

7. Palliative Care: For advanced HF (Stage D) not amenable to advanced therapies.

---

Management of HFrEF (LVEF less than 40%)

HFrEF has the strongest evidence base for therapies that reduce mortality and morbidity. [24]

The Four Pillars of GDMT

All four drug classes should be initiated in all eligible patients unless contraindicated. [1,24] Sequential initiation is no longer recommended; contemporary approach is rapid up-titration of all four pillars.

┌─────────────────────────────────────────────────────────────────────────────┐
│                    HFrEF MANAGEMENT PROTOCOL (LVEF less than 40%)                    │
├─────────────────────────────────────────────────────────────────────────────┤
│                                                                             │
│   FOUNDATIONAL THERAPY: DIURETICS (Symptom Control Only)                    │
│   ┌───────────────────────────────────────────────────────────────────┐     │
│   │ • Loop Diuretics: Furosemide 20-240 mg/day OR Bumetanide 1-5 mg/day│     │
│   │ • Relieve congestion (dyspnea, edema)                              │     │
│   │ • NO mortality benefit - use lowest effective dose                 │     │
│   │ • Monitor: Weight, symptoms, renal function, electrolytes          │     │
│   └───────────────────────────────────────────────────────────────────┘     │
│                                    ↓                                        │
│   THE FOUR PILLARS (Prognostic Benefit - Start ALL)                         │
│                                                                             │
│   ┌───────────────────────────────────────────────────────────────────┐     │
│   │ PILLAR 1: RAAS INHIBITION                                          │     │
│   │                                                                     │     │
│   │ First Choice: ARNI (Angiotensin Receptor-Neprilysin Inhibitor)     │     │
│   │ • Sacubitril/Valsartan (Entresto)                                  │     │
│   │   - Start: 49/51 mg BD, target 97/103 mg BD                        │     │
│   │   - Superior to ACEi (PARADIGM-HF: 20% mortality reduction) [25]   │     │
│   │   - Do NOT combine with ACEi (angioedema risk)                     │     │
│   │   - Wait 36h after last ACEi dose before starting                  │     │
│   │                                                                     │     │
│   │ Alternative: ACE Inhibitor                                         │     │
│   │ • Ramipril: Start 1.25-2.5 mg OD, target 10 mg OD                  │     │
│   │ • Enalapril: Start 2.5 mg BD, target 10-20 mg BD                   │     │
│   │ • Lisinopril: Start 2.5-5 mg OD, target 20-40 mg OD                │     │
│   │                                                                     │     │
│   │ Second Alternative: ARB (if ACEi-intolerant due to cough)          │     │
│   │ • Candesartan: Start 4-8 mg OD, target 32 mg OD                    │     │
│   │ • Valsartan: Start 40 mg BD, target 160 mg BD                      │     │
│   │                                                                     │     │
│   │ Monitoring: BP, renal function, K+ at 1-2 weeks                    │     │
│   │ Acceptable changes: SBP > 90, Cr less than 266 μmol/L, K less than 5.5 mmol/L         │     │
│   └───────────────────────────────────────────────────────────────────┘     │
│                                                                             │
│   ┌───────────────────────────────────────────────────────────────────┐     │
│   │ PILLAR 2: BETA-BLOCKER                                             │     │
│   │                                                                     │     │
│   │ Evidence-Based Agents (Use ONLY these):                            │     │
│   │ • Bisoprolol: Start 1.25 mg OD, target 10 mg OD                    │     │
│   │ • Carvedilol: Start 3.125 mg BD, target 25-50 mg BD                │     │
│   │ • Metoprolol succinate: Start 12.5-25 mg OD, target 200 mg OD      │     │
│   │                                                                     │     │
│   │ Benefits: 35% mortality reduction, reduce SCD, improve LVEF [26]   │     │
│   │                                                                     │     │
│   │ Initiation: Start low, go slow (double dose every 2-4 weeks)       │     │
│   │ • ONLY in euvolemic (dry) patients                                 │     │
│   │ • NEVER start in acute pulmonary edema                             │     │
│   │ • Target resting HR: 50-60 bpm                                     │     │
│   │                                                                     │     │
│   │ Monitoring: HR, BP, symptoms of decompensation                     │     │
│   │ Acceptable: HR > 50 bpm, SBP > 90 mmHg                               │     │
│   └───────────────────────────────────────────────────────────────────┘     │
│                                                                             │
│   ┌───────────────────────────────────────────────────────────────────┐     │
│   │ PILLAR 3: MINERALOCORTICOID RECEPTOR ANTAGONIST (MRA)              │     │
│   │                                                                     │     │
│   │ Agents:                                                            │     │
│   │ • Spironolactone: Start 12.5-25 mg OD, target 25-50 mg OD          │     │
│   │ • Eplerenone: Start 25 mg OD, target 50 mg OD (if gynecomastia)    │     │
│   │                                                                     │     │
│   │ Benefits: Blocks aldosterone-mediated fibrosis                     │     │
│   │ • 30% mortality reduction (RALES trial) [27]                       │     │
│   │ • Anti-fibrotic, anti-remodeling effects                           │     │
│   │                                                                     │     │
│   │ Critical Monitoring: HYPERKALEMIA RISK                             │     │
│   │ • Check K+ and Cr at 1, 4, 8, 12 weeks, then 6-monthly             │     │
│   │ • Hold if K+ > 5.5 mmol/L                                           │     │
│   │ • Avoid if baseline K+ > 5.0 mmol/L or Cr > 221 μmol/L               │     │
│   │                                                                     │     │
│   │ Side effects: Gynecomastia (10-15%), hyperkalemia                  │     │
│   └───────────────────────────────────────────────────────────────────┘     │
│                                                                             │
│   ┌───────────────────────────────────────────────────────────────────┐     │
│   │ PILLAR 4: SGLT2 INHIBITOR                                          │     │
│   │                                                                     │     │
│   │ Evidence-Based Agents:                                             │     │
│   │ • Dapagliflozin: 10 mg OD                                          │     │
│   │ • Empagliflozin: 10 mg OD                                          │     │
│   │                                                                     │     │
│   │ Landmark Trials:                                                   │     │
│   │ • DAPA-HF: 26% reduction in CV death/HF hospitalization [28]       │     │
│   │ • EMPEROR-Reduced: 25% reduction in CV death/HF hospitalization[29]│     │
│   │                                                                     │     │
│   │ Benefits:                                                          │     │
│   │ • Effective regardless of diabetes status                          │     │
│   │ • Rapid benefit (within weeks)                                     │     │
│   │ • Well tolerated, minimal contraindications                        │     │
│   │ • Natriuretic effect (reduces congestion)                          │     │
│   │ • Metabolic benefits                                               │     │
│   │                                                                     │     │
│   │ Precautions:                                                       │     │
│   │ • Ensure adequate hydration (avoid if volume depleted)             │     │
│   │ • Monitor for genital mycotic infections (5-10%)                   │     │
│   │ • DKA risk minimal in non-T1DM                                     │     │
│   │ • Safe to eGFR > 20 mL/min/1.73m²                                   │     │
│   └───────────────────────────────────────────────────────────────────┘     │
│                                                                             │
├─────────────────────────────────────────────────────────────────────────────┤
│   SEQUENTIAL THERAPY (If symptoms persist despite 4 pillars)                │
│                                                                             │
│   5th Line Options:                                                         │
│   • Ivabradine (if sinus rhythm + HR > 70 despite beta-blocker)              │
│   • Hydralazine + Isosorbide Dinitrate (self-identified Black patients)     │
│   • Vericiguat (if recent decompensation)                                   │
│   • Digoxin (if AF or persistent symptoms)                                  │
│                                                                             │
├─────────────────────────────────────────────────────────────────────────────┤
│   DEVICE THERAPY (if EF ≤35% after 3-6 months optimal medical therapy)      │
│                                                                             │
│   ICD (Implantable Cardioverter-Defibrillator):                            │
│   • Primary prevention SCD                                                  │
│   • Indicated: LVEF ≤35%, NYHA II-III, > 1 year life expectancy             │
│   • 23% mortality reduction [30]                                            │
│                                                                             │
│   CRT-D (Cardiac Resynchronization Therapy):                                │
│   • Biventricular pacing + defibrillator                                    │
│   • Indicated: LVEF ≤35%, NYHA II-IV, QRS ≥130 ms (esp. LBBB pattern)      │
│   • Improves symptoms, LVEF, reduces mortality [31]                         │
│                                                                             │
└─────────────────────────────────────────────────────────────────────────────┘

Additional Pharmacological Therapies

Ivabradine:

• Mechanism: Selective If channel inhibitor; reduces heart rate without negative inotropy
• Indication: Sinus rhythm, LVEF ≤35%, HR ≥70 bpm despite maximum tolerated beta-blocker (or beta-blocker contraindication), NYHA II-IV
• Dose: Start 2.5-5 mg BD, target HR 50-60 bpm
• Evidence: 18% reduction in CV death/HF hospitalization (SHIFT trial)
• Contraindications: Atrial fibrillation, sick sinus syndrome, pacemaker dependency

Hydralazine + Isosorbide Dinitrate (H-ISDN):

• Indication: Self-identified Black patients (genetic differences in nitric oxide bioavailability); alternative if ACEi/ARB/ARNI intolerant
• Dose: Hydralazine 37.5-75 mg TDS + ISDN 20-40 mg TDS
• Evidence: 43% mortality reduction in Black patients (A-HeFT trial)
• Side effects: Headache, dizziness, drug-induced lupus (hydralazine)

Vericiguat:

• Mechanism: Soluble guanylate cyclase stimulator
• Indication: Worsening HF despite GDMT (recent hospitalization or IV diuretic need)
• Dose: Start 2.5 mg OD, target 10 mg OD
• Evidence: 10% reduction in CV death/HF hospitalization (VICTORIA trial)
• Position: Not routinely used; niche role in advanced HF

Digoxin:

• Indication: Symptomatic improvement in persistent NYHA III-IV despite GDMT; rate control in AF
• Dose: 62.5-250 μg OD (lower in elderly, renal impairment)
• Evidence: Reduces HF hospitalization, NO mortality benefit (DIG trial)
• Monitoring: Renal function, electrolytes (hypokalemia increases toxicity), narrow therapeutic index
• Toxicity: Nausea, confusion, visual disturbances (yellow halos), arrhythmias

Device Therapy

Implantable Cardioverter-Defibrillator (ICD):

• Primary Prevention Indication: [30]
  • LVEF ≤35% despite ≥3 months optimal medical therapy
  • NYHA class II-III
  • Ischemic cardiomyopathy (> 40 days post-MI) OR non-ischemic DCM
  • Life expectancy > 1 year with good functional status
• Secondary Prevention: Survived cardiac arrest or sustained VT
• Benefit: 23% mortality reduction (SCD-HeFT trial)
• Contraindications: Advanced HF (NYHA IV refractory), terminal illness, frequent VT storms

Cardiac Resynchronization Therapy (CRT): [31]

• Mechanism: Biventricular pacing corrects electrical dyssynchrony (LBBB causes left ventricle to contract late)
• Indications:
  • LVEF ≤35%
  • NYHA II-IV despite optimal medical therapy
  • QRS duration ≥130 ms with LBBB morphology (strongest indication)
  • Sinus rhythm (AF patients require AVN ablation for reliable pacing)
• Benefits: Improves symptoms, quality of life, LVEF (5-10% absolute increase), reduces HF hospitalization, 36% mortality reduction
• Response: 60-70% respond; non-response associated with non-LBBB pattern, RV pacing, suboptimal lead position, severe scar burden
• CRT-P vs CRT-D: CRT-P (pacemaker only) if ICD not indicated; CRT-D (defibrillator + pacing) preferred if ICD criteria met

---

Management of HFmrEF (LVEF 41-49%)

HFmrEF represents an intermediate phenotype; may be patients recovering from HFrEF or transitioning to HFrEF. [8]

Approach: Treat as HFrEF with four-pillar GDMT.

Evidence: Limited dedicated trials; post-hoc analyses suggest benefit from RAAS inhibitors, beta-blockers, MRAs; SGLT2 inhibitors effective (DELIVER trial included HFmrEF).

Monitoring: Serial echocardiography to assess trajectory (improving vs. declining LVEF).

---

Management of HFpEF (LVEF ≥50%)

HFpEF historically lacked proven therapies, but recent trials have shown benefit from SGLT2 inhibitors. [1]

Evidence-Based Therapies

SGLT2 Inhibitors (THE KEY THERAPY):

• Dapagliflozin: DELIVER trial - 18% reduction in CV death/HF hospitalization in HFpEF [32]
• Empagliflozin: EMPEROR-Preserved trial - 21% reduction in CV death/HF hospitalization [33]
• Recommendation: First-line therapy for all HFpEF patients
• Dose: Dapagliflozin 10 mg OD or Empagliflozin 10 mg OD

Diuretics:

• Loop diuretics for congestion (symptom relief)
• No mortality benefit but essential for quality of life

Treat Underlying Causes and Comorbidities:

• Hypertension: Aggressive BP control (target less than 130/80 mmHg); ACEi, ARB, diuretics, CCBs
• Atrial Fibrillation: Rate control (beta-blockers, digoxin), rhythm control if appropriate, anticoagulation
• Obesity: Weight loss improves symptoms
• Diabetes: Optimal glycemic control; SGLT2i dual benefit
• Ischemia: Revascularization if indicated
• OSA: CPAP therapy

Therapies WITHOUT Proven Benefit in HFpEF:

• ACE inhibitors / ARBs: Neutral results (CHARM-Preserved, I-PRESERVE, PEP-CHF)
• MRAs: Trend toward benefit but not statistically significant (TOPCAT trial - geographical heterogeneity)
• Beta-blockers: No specific HFpEF trial evidence

Specific HFpEF Phenotypes

HFpEF with Atrial Fibrillation: Rhythm control strategy (cardioversion, ablation) may be more beneficial than in HFrEF.

HFpEF with Obesity/Metabolic Syndrome: SGLT2i particularly effective; consider GLP-1 agonists for weight reduction.

HFpEF with Amyloidosis: Refer to specialist; tafamidis for transthyretin amyloidosis.

---

Management of Acute Decompensated Heart Failure

Acute decompensation requires hospital admission and urgent treatment. [1]

Immediate Assessment:

• Airway, Breathing, Circulation
• Oxygen saturation, consider supplemental O2 (target SpO2 94-98%)
• IV access, ECG, CXR, bloods (including troponin, BNP)

Initial Management:

1. IV Loop Diuretics: Furosemide 40-80 mg IV bolus (or 2× usual oral dose), repeat or infusion if inadequate response
2. Vasodilators (if SBP > 110 mmHg): GTN infusion or buccal GTN
3. Oxygen: Non-invasive ventilation (CPAP/BiPAP) if respiratory failure
4. Treat Precipitants: Arrhythmia, ACS, infection, medication non-adherence

Inotropes/Vasopressors (cardiogenic shock only, ICU setting):

• Dobutamine (inotrope)
• Norepinephrine (vasopressor)
• Levosimendan (calcium sensitizer)

---

Lifestyle and Non-Pharmacological Management

Sodium Restriction: less than 2-3 g/day (5-6 g salt); reduces fluid retention. [1]

Fluid Restriction: Generally NOT recommended unless severe hyponatremia (less than 130 mmol/L); restriction to 1.5-2 L/day may help.

Exercise Training:

• Cardiac Rehabilitation: Supervised exercise programs improve functional capacity, quality of life, reduce hospitalization
• Recommendation: 30 minutes moderate aerobic exercise 5×/week after stabilization

Alcohol: Abstinence if alcohol-induced cardiomyopathy; moderation (less than 1-2 units/day) otherwise.

Smoking Cessation: Essential.

Weight Monitoring: Daily weights; report gain > 2 kg in 3 days (suggests fluid retention).

Vaccinations: Annual influenza, pneumococcal, COVID-19 (reduces infection-related decompensation).

Diet: Balanced, Mediterranean-style diet; avoid excess fluids.

Psychosocial Support: Depression common (20-40%); screening and treatment improves outcomes.

---

Monitoring and Follow-up

Frequency: Intensive initially (weekly/biweekly during titration), then stable patients every 3-6 months.

Clinical Assessment: Symptoms (NYHA class), signs (congestion, perfusion), weight, BP, HR.

Blood Tests:

• Renal function and electrolytes: 1-2 weeks after starting/up-titrating RAAS inhibitors or MRAs, then 3-6 monthly
• BNP/NT-proBNP: Useful for monitoring; rising levels predict decompensation

Echocardiography: Reassess LVEF at 3-6 months after initiating GDMT (may improve; affects device decisions), then annually or if clinical change.

Device Monitoring: Remote monitoring of ICD/CRT (arrhythmias, lead function, pacing burden).

Multidisciplinary Team: HF specialist nurses, pharmacists, dietitians, physiotherapists.

---

6. Complications

1. Sudden Cardiac Death (SCD)

Mechanism: Ventricular arrhythmias (VF, VT); most common cause of death in HFrEF (especially NYHA II-III). [30]

Prevention: ICD (primary prevention in LVEF ≤35%).

Risk Factors: Low LVEF, ischemic etiology, non-sustained VT, syncope.

2. Progressive Pump Failure

Presentation: Gradual decline despite medical therapy; refractory symptoms.

Management: Advanced therapies (LVAD, heart transplant), palliative care.

3. Cardiorenal Syndrome

Definition: Worsening renal function in context of acute or chronic HF.

Types:

• Type 1: Acute HF → acute kidney injury
• Type 2: Chronic HF → chronic kidney disease
• Type 3: Acute kidney injury → acute HF
• Type 4: Chronic kidney disease → chronic HF
• Type 5: Systemic disease → both

Mechanism: Reduced renal perfusion, venous congestion, neurohormonal activation, inflammation.

Management: Optimize HF therapy (diuretics for congestion, GDMT), avoid nephrotoxins, consider ultrafiltration in refractory cases.

4. Arrhythmias

Atrial Fibrillation: Present in 30-50%; worsens HF; requires rate/rhythm control and anticoagulation.

Ventricular Arrhythmias: VT/VF; ICD indicated.

5. Thromboembolism

Risk: Stasis (dilated ventricles, AF), LV thrombus, stroke.

Anticoagulation: Indicated for AF (CHA2DS2-VASc score), LV thrombus (3-6 months), or history of thromboembolism.

6. Cachexia

Definition: Involuntary weight loss > 5% over 6 months.

Mechanism: Increased metabolic rate, reduced intake, GI malabsorption, inflammation.

Prognosis: Poor; indicates advanced HF.

Management: Nutritional support, appetite stimulants (limited evidence), address underlying HF.

7. Iron Deficiency

Prevalence: 40-50% of HF patients. [23]

Definition: Ferritin less than 100 μg/L OR ferritin 100-299 μg/L with transferrin saturation less than 20%.

Impact: Worsens fatigue, exercise intolerance, quality of life; independent of anemia.

Treatment: IV ferric carboxymaltose (CONFIRM-HF, AFFIRM-AHF trials) - improves symptoms, functional capacity, quality of life, reduces HF hospitalization. [23]

---

7. Prognosis

Mortality

Overall: 5-year mortality ~50% (comparable to many cancers). [6]

By NYHA Class:

• NYHA I: 5-10% annual mortality
• NYHA II: 10-20%
• NYHA III: 20-40%
• NYHA IV: 40-60%

Improvement with GDMT: Contemporary four-pillar therapy significantly improves prognosis; combined mortality reduction estimated 50-60% vs. placebo. [24]

Prognostic Factors

Favorable:

• Higher LVEF
• Lower NYHA class
• Lower BNP/NT-proBNP
• Younger age
• Non-ischemic etiology
• Normal renal function
• Normal sodium
• Adherence to GDMT

Unfavorable:

• Very low LVEF (less than 20%)
• Advanced NYHA (III-IV)
• Elevated BNP/NT-proBNP
• Hyponatremia (less than 135 mmol/L)
• Renal dysfunction (eGFR less than 30)
• Cachexia
• Frequent hospitalizations
• Ischemic etiology
• Persistent symptoms despite GDMT

Heart Failure Hospitalization

Impact: Each hospitalization associated with increased mortality risk; 30-day readmission rate 20-25%.

Prevention: Optimal medical therapy, patient education, multidisciplinary follow-up, early recognition of decompensation.

---

8. Advanced Heart Failure and Palliative Care

Advanced Heart Failure (Stage D)

Definition: Refractory symptoms (NYHA III-IV) despite maximum tolerated GDMT and device therapy; frequent hospitalizations.

Advanced Therapies:

1. Left Ventricular Assist Device (LVAD):

   • Mechanical pump supporting LV function
   • Bridge to transplant: Temporary support awaiting heart
   • Destination therapy: Permanent therapy in transplant-ineligible patients
   • Improves survival and quality of life vs. medical therapy alone

2. Heart Transplantation:

   • Definitive treatment for end-stage HF
   • Indications: Age less than 65-70 years, refractory HF, no significant comorbidities, psychosocially stable
   • 1-year survival: ~90%; 5-year survival: ~75%
   • Limitations: Donor shortage, immunosuppression, rejection, cardiac allograft vasculopathy

Inotropic Therapy:

• Continuous or intermittent IV inotropes (dobutamine, milrinone)
• Palliative measure to improve symptoms
• No mortality benefit; may increase arrhythmia risk

Palliative Care

Indications: Advanced HF not suitable for transplant/LVAD, multiple hospitalizations, refractory symptoms, patient preference.

Goals: Symptom control (dyspnea, pain, anxiety), psychosocial support, advanced care planning, end-of-life discussions.

Symptom Management:

• Dyspnea: Opioids (morphine), benzodiazepines, oxygen
• Fluid overload: Continued diuretics
• Withdrawal of non-symptomatic medications: ICD deactivation discussions

---

9. Key Clinical Pearls

Exam-Focused High-Yield Points

1. Beta-Blockers: NEVER start in acute pulmonary edema or decompensated HF. Wait until euvolemic ("dry"). Start low, go slow to avoid worsening HF.

2. SGLT2 Inhibitors: The "wonder drug" for HF. Effective in HFrEF, HFpEF, and CKD. Works regardless of diabetes status. Rapid onset of benefit.

3. BNP Interpretation Pitfalls:

   • False Lows: Obesity (reduce threshold by 50% if BMI > 35), flash pulmonary edema (insufficient time for release)
   • False Highs: Age > 70, AF, CKD, PE, sepsis, RV strain

4. Normal ECG: Makes HF unlikely (95% NPV). If ECG and BNP both normal, HF highly unlikely.

5. Device Criteria: ICD if LVEF ≤35%. CRT if LVEF ≤35% + QRS ≥130 ms + LBBB morphology.

6. Spironolactone: Watch potassium closely (risk of hyperkalemia, especially with ACEi/ARB/ARNI). Gynecomastia side effect (10-15%) - switch to eplerenone.

7. ARNI: Superior to ACEi (PARADIGM-HF: 20% mortality reduction). Now often first-line. Do NOT combine with ACEi (angioedema risk). Wait 36 hours after last ACEi dose.

8. HFpEF: Only proven therapy is SGLT2 inhibitors (dapagliflozin, empagliflozin). ACEi/ARBs do NOT reduce mortality in HFpEF.

9. Iron Deficiency: Screen all HF patients. Treat with IV iron (ferric carboxymaltose) if ferritin less than 100 OR ferritin 100-299 with TSAT less than 20%. Improves symptoms even without anemia.

10. Diuretics: Provide symptom relief but NO mortality benefit. Use lowest effective dose. Resistance is common; may require higher doses or combination with thiazide.

Common Exam Scenarios

Scenario 1: Adding to Therapy

Stem: "68-year-old with HFrEF (LVEF 30%) on Ramipril 10 mg OD and Bisoprolol 10 mg BD. Still breathless NYHA class III. What is the most appropriate next step?"

Answer: Add Spironolactone 25 mg OD OR Dapagliflozin 10 mg OD. Could also consider switching Ramipril to Sacubitril/Valsartan. All four pillars should be initiated.

Teaching Point: Four-pillar therapy (RAAS inhibitor, beta-blocker, MRA, SGLT2i) - patient currently on only 2 pillars.

---

Scenario 2: Diuretic Resistance

Stem: "72-year-old on Furosemide 80 mg BD for HF, but ankles remain swollen and breathless. What would you do?"

Answer:

1. Assess compliance and salt intake
2. Check renal function (worsening renal function reduces diuretic efficacy)
3. Increase furosemide dose OR switch to more potent loop (bumetanide)
4. Add thiazide (metolazone) for sequential nephron blockade
5. Ensure on optimal GDMT (not just diuretics)
6. Consider IV diuretics if oral absorption impaired (gut edema)

Teaching Point: Diuretic resistance is common in chronic HF due to renal dysfunction, neurohormonal activation, and compensatory tubular hypertrophy.

---

Scenario 3: HFpEF

Stem: "70-year-old woman with dyspnea, ankle swelling, elevated BNP. Echo shows LVEF 60% with impaired diastolic function and LA enlargement. Diagnosis is HFpEF. What treatment would you start?"

Answer: Dapagliflozin 10 mg OD (or empagliflozin). Also diuretics for symptom control. Treat hypertension, AF, other comorbidities.

Teaching Point: SGLT2 inhibitors are the ONLY proven therapy for HFpEF. ACEi/ARBs do NOT reduce mortality in HFpEF.

---

Scenario 4: Device Therapy

Stem: "55-year-old with ischemic cardiomyopathy, LVEF 28%, NYHA class II on optimal medical therapy for 6 months. ECG shows LBBB with QRS 150 ms. What device therapy is indicated?"

Answer: CRT-D (Cardiac Resynchronization Therapy with Defibrillator).

• ICD indicated: LVEF ≤35%, ischemic, NYHA II, > 40 days post-MI
• CRT indicated: LVEF ≤35%, QRS ≥130 ms with LBBB, NYHA II-IV

Teaching Point: Wide LBBB (QRS > 130 ms) indicates ventricular dyssynchrony; CRT corrects this and improves outcomes. CRT-D combines pacing with defibrillator.

---

Scenario 5: Acute Decompensation

Stem: "Presenting with acute pulmonary edema. Currently on Ramipril, Bisoprolol, Spironolactone. What immediate management?"

Answer:

1. Sit upright, high-flow oxygen (target SpO2 94-98%)
2. IV furosemide 40-80 mg bolus
3. GTN (sublingual or IV infusion if SBP > 110)
4. Consider CPAP/BiPAP if Type 1 respiratory failure
5. Do NOT stop chronic medications (common mistake)

Teaching Point: Do NOT stop beta-blockers or other GDMT in acute decompensation unless cardiogenic shock. Continue chronic therapies and add acute therapies (diuretics, vasodilators, ventilatory support).

---

Scenario 6: Medication Contraindication

Stem: "Patient develops dry cough on ACEi. What alternative?"

Answer: ARB (e.g., Candesartan, Valsartan). OR switch directly to ARNI (Sacubitril/Valsartan) if not already on it.

Teaching Point: Cough is ACEi-specific (bradykinin accumulation); ARBs do not cause cough. Angioedema is a class effect (ACEi and ARB) - absolute contraindication to both; use hydralazine-nitrate instead.

---

10. Patient Explanation

"Is my heart stopping?"

"No, the term 'heart failure' is confusing and scary, but your heart is not stopping or about to stop. It means your heart muscle has become weaker and isn't pumping as efficiently as it used to - like an engine running on 3 cylinders instead of 4. The good news is that we have excellent medications that strengthen the heart, reduce the workload, and help it work more efficiently. Many patients live full, active lives with heart failure when it's well managed."

"Why do I have to take so many tablets?"

"Each medication works in a different way to help your heart:

• One reduces the strain on your heart (ACE inhibitor or Entresto)
• One slows and strengthens the heartbeat (beta-blocker)
• One prevents scarring of the heart muscle (spironolactone)
• One helps your kidneys remove excess fluid and has special heart-protective effects (SGLT2 inhibitor)
• The water tablet (furosemide) helps with breathlessness and swelling

Together, these medications have been proven in large studies to help people live longer, stay out of hospital, and feel better. It's like a team working together - each player has a specific role."

"Can I stop the water tablets when I feel better?"

"The water tablets (diuretics) help clear the fluid buildup that makes you breathless and swollen, but they don't fix the underlying heart problem. The other medications (ACE inhibitor, beta-blocker, spironolactone, SGLT2 inhibitor) are the ones that actually protect and strengthen your heart muscle.

If you stop the water tablets when you feel better, the fluid will come back and you'll become breathless and swollen again. We'll use the lowest dose that keeps you comfortable. If you're feeling very well with no swelling or breathlessness, we can discuss reducing the dose, but don't stop it without talking to us first."

"Will my heart get better?"

"That depends. In some people, especially if we catch it early and start the right medications, the heart muscle can recover and strengthen - sometimes the heart function improves significantly. In others, the heart doesn't fully recover, but the medications prevent it from getting worse and help you feel much better.

What we know for certain is that the medications we're prescribing have been proven to help people live longer and stay out of hospital. Regular follow-up and monitoring are important so we can adjust your treatment as needed."

"What should I avoid?"

"The most important things are:

• Salt: Too much salt makes your body hold onto water, worsening the swelling and breathlessness. Try to keep salt intake low.
• Excess fluids: Drinking large amounts can worsen fluid overload. Aim for 1.5-2 liters per day unless we advise otherwise.
• Alcohol: If alcohol caused your heart problem, you must stop completely. Otherwise, limit to 1-2 units per day maximum.
• Smoking: Absolutely stop - it damages blood vessels and makes heart failure worse.
• Missing medications: Skipping doses can lead to worsening of your condition.

What you SHOULD do:

• Weigh yourself daily: Report sudden weight gain (> 2 kg in 3 days)
• Stay active: Gentle regular exercise (walking) helps - we can refer you to cardiac rehabilitation
• Get vaccinated: Flu and pneumonia vaccines reduce risk of infections that can worsen heart failure
• Attend appointments: Regular monitoring helps us optimize your treatment"

---

11. Evidence & Guidelines

Key Guidelines

Landmark Trials

RAAS Inhibition

Beta-Blockers

SGLT2 Inhibitors

Device Therapy

Evidence-Based Recommendations Summary

---

12. Summary: The Modern Approach to Heart Failure

Heart Failure in 2026 is no longer a death sentence. The contemporary four-pillar approach (ARNI/ACEi + Beta-Blocker + MRA + SGLT2i) has revolutionized outcomes:

1. Combined Mortality Reduction: Approximately 50-60% relative risk reduction vs. placebo with full GDMT
2. SGLT2 Inhibitors: Game-changer; effective in HFrEF AND HFpEF, with or without diabetes
3. Early Initiation: Start all four pillars rapidly; sequential titration no longer recommended
4. Device Therapy: ICD and CRT for selected patients; additional survival benefit
5. Holistic Care: Multidisciplinary approach, lifestyle modifications, comorbidity management, palliative care for advanced disease

Bottom Line: Heart failure is a chronic, progressive syndrome requiring lifelong management. With evidence-based therapies, most patients can achieve symptom control, improved quality of life, and prolonged survival. Early diagnosis, aggressive medical therapy, and regular monitoring are key to optimal outcomes.

---

13. References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726. doi:10.1093/eurheartj/ehab368

2. Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2

3. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. Nat Rev Cardiol. 2016;13(6):368-378. doi:10.1038/nrcardio.2016.25

4. Bleumink GS, Knetsch AM, Sturkenboom MC, et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. Eur Heart J. 2004;25(18):1614-1619. doi:10.1016/j.ehj.2004.06.038

5. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure. J Am Coll Cardiol. 2014;63(12):1123-1133. doi:10.1016/j.jacc.2013.11.053

6. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-1402. doi:10.1056/NEJMoa020265

7. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. Int J Cardiol. 2014;171(3):368-376. doi:10.1016/j.ijcard.2013.12.028

8. Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction. Circ J. 2017;81(12):1883-1891. doi:10.1253/circj.CJ-17-0501

9. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little, Brown & Co; 1994:253-256.

10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure. Circulation. 2013;128(16):e240-e327. doi:10.1161/CIR.0b013e31829e8776

11. Mann DL, Bristow MR. Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation. 2005;111(21):2837-2849. doi:10.1161/CIRCULATIONAHA.104.500546

12. Velagaleti RS, Pencina MJ, Murabito JM, et al. Long-term trends in the incidence of heart failure after myocardial infarction. Circulation. 2008;118(20):2057-2062. doi:10.1161/CIRCULATIONAHA.108.784215

13. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123(3):327-334. doi:10.1161/CIRCULATIONAHA.108.845792

14. Schultheiss HP, Fairweather D, Caforio ALP, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019;5(1):32. doi:10.1038/s41572-019-0084-1

15. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications. J Am Coll Cardiol. 2000;35(3):569-582. doi:10.1016/s0735-1097(99)00630-0

16. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure. J Am Coll Cardiol. 2009;54(19):1747-1762. doi:10.1016/j.jacc.2009.05.015

17. Thibodeau JT, Turer AT, Gualano SK, et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014;2(1):24-31. doi:10.1016/j.jchf.2013.07.009

18. Drazner MH, Rame JE, Stevenson LW, Dries DL. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med. 2001;345(8):574-581. doi:10.1056/NEJMoa010641

19. Marcus GM, Gerber IL, McKeown BH, et al. Association between phonocardiographic third and fourth heart sounds and objective measures of left ventricular function. JAMA. 2005;293(18):2238-2244. doi:10.1001/jama.293.18.2238

20. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. doi:10.1056/NEJMoa020233

21. Davie AP, Francis CM, Love MP, et al. Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction. BMJ. 1996;312(7025):222. doi:10.1136/bmj.312.7025.222

22. Pieske B, Tschöpe C, de Boer RA, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm. Eur Heart J. 2019;40(40):3297-3317. doi:10.1093/eurheartj/ehz641

23. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-668. doi:10.1093/eurheartj/ehu385

24. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Circulation. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063

25. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993-1004. doi:10.1056/NEJMoa1409077

26. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353(9146):9-13. doi:10.1016/s0140-6736(98)11181-9

27. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341(10):709-717. doi:10.1056/NEJM199909023411001

28. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction (DAPA-HF). N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303

29. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure (EMPEROR-Reduced). N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190

30. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure (SCD-HeFT). N Engl J Med. 2005;352(3):225-237. doi:10.1056/NEJMoa043399

31. Cleland JGF, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure (CARE-HF). N Engl J Med. 2005;352(15):1539-1549. doi:10.1056/NEJMoa050496

32. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER). N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286

33. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction (EMPEROR-Preserved). N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038